Detection of candidate biomarkers of prostate cancer progression in serum : a depletion-free 3D LC/MS quantitative proteomics pilot study
Menée sur 79 échantillons sériques prélevés sur des patients présentant une maladie bénigne ou un cancer de stade TI à TIV de la prostate, puis validée sur 80 autres échantillons sériques, cette étude identifie, à l'aide d'une technique de spectrométrie de masse quantitative, des biomarqueurs candidats de la progression du cancer de la prostate
Background : Prostate cancer (PCa) is the most common male cancer in the United Kingdom and we aimed to identify clinically relevant biomarkers corresponding to stage progression of the disease.
Methods : We used enhanced proteomic profiling of PCa progression using iTRAQ 3D LC mass spectrometry on high-quality serum samples to identify biomarkers of PCa.
Results : We identified >1000 proteins. Following specific inclusion/exclusion criteria we targeted seven proteins of which two were validated by ELISA and six potentially interacted forming an ‘interactome’ with only a single protein linking each marker. This network also includes accepted cancer markers, such as TNF, STAT3, NF-
κB and IL6.
Conclusions
:
Our linked and interrelated biomarker network highlights the potential utility of six of our seven markers as a panel for diagnosing PCa and, critically, in determining the stage of the disease. Our validation analysis of the MS-identified proteins found that SAA alongside KLK3 may improve categorisation of PCa than by KLK3 alone, and that TSR1, although not significant in this model, might also be a clinically relevant biomarker.
British Journal of Cancer , article en libre accès, 2015